Press release content from Business Wire. The AP news staff was not involved in its creation.
Newron and Zambon Sign Agreement for Potentially Pivotal Study with safinamide in Parkinson’s Disease Patients
March 15, 2021 GMT
MILAN (BUSINESS WIRE) Mar 15, 2021
Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system and its partner, Zambon S.p.A. (“Zambon”), an international pharmaceutical company strongly committed to the central nervous system (CNS) therapeutic area, today announced an agreement regarding a potentially pivotal study to evaluate the efficacy of
Xadago® in the rest of the world.
References:
Movement disorders : official journal of the Movement Disorder Society vol. 29 (10) p. 1273-80.
Anand R: Safinamide is associated with clinically important improvement in motor symptoms in fluctuating PD patients as add-on to levodopa (SETTLE). 17th International Congress of Parkinson’s Disease and Movement Disorders, Sydney, Australia, June 16-20, 2013.
About Parkinson’s disease and Levodopa (L-dopa) Induced Dyskinesia (LID)
PD is the second most common chronic progressive neurodegenerative disorder in the elderly after Alzheimer’s disease, affecting 1-2% of individuals aged ≥ 65 years worldwide. The prevalence of the PD market is expected to grow in the next years due to the increase in the global population and advancements in healthcare that contribute to an aging population at increased risk for PD. The diagnosis of PD is mainly based on observational criteria of muscular rigidity, resting tremor, or postural instabil
World Federation of Neurology Launches Global Brain Health Awareness Campaign
USA - English
News provided by
Share this article
Share this article
LONDON, Feb. 12, 2021 /PRNewswire/ The World Federation of Neurology is pleased to announce its launch of the Brain Health Initiative, a global campaign to promote the importance of brain health. This initiative centers upon free, comprehensive information on a variety of topics such as why brain health is important and what happens when brains are not healthy. The programming aims to reduce the burden of brain diseases and disorders, which are the second leading cause of death globally.
Prothena Corporation plc: Prothena Reports Fourth Quarter and Full Year 2020 Financial Results, and Provides Financial Guidance and R&D Update
VITAL study 9-month results expected to be presented at medical conference in 2021
Prasinezumab
New pre-specified exploratory subgroup analyses from Part 1 of the Phase 2 PASADENA study to be presented at the 15th International Conference for Alzheimer s and Parkinson s Diseases in March 2021 (ADPD 2021)
$60 million clinical milestone payment to be achieved upon first patient dosed in late-stage Phase 2b study in patients with early Parkinson s disease; further details expected in 2Q 2021
Results from Part 2 of the PASADENA study expected to be presented at an upcoming medical conference